Retatrutide Explained: The Triple Agonist Changing Obesity Medicine

Retatrutide may represent the next evolution in metabolic medicine.In this deep-dive episode of Peptides Explained, we break down the science behind the investigational “triple agonist” peptide that’s generating major attention in obesity and metabolic research.Topics covered:• GLP-1 + GIP + glucagon receptor activation• How retatrutide differs from semaglutide and tirzepatide• Phase 2 clinical trial results• Fat loss vs lean mass loss• Liver fat reduction data• The emerging discussion around obesity-related cancer risk• What may happen after discontinuation• Known side effects and unanswered questionsThis episode goes beyond headlines and social media hype to explain the actual biology and human data behind retatrutide.Peptides Explained is focused on evidence, mechanism, and clarity.This podcast is for educational purposes only and is not medical advice.